The Cost of Control: Cost-effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth | Zendy

Anthony Pease | Zendy; Emily Callander | Zendy; Ella Zomer | Zendy; Mary B. Abraham | Zendy; Elizabeth A. Davis | Zendy; Timothy W. Jones | Zendy; Danny Liew | Zendy; Sophia Zoungas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Cost of Control: Cost-effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth

Author(s) -

Anthony Pease,

Emily Callander,

Ella Zomer,

Mary B. Abraham,

Elizabeth A. Davis,

Timothy W. Jones,

Danny Liew,

Sophia Zoungas

Publication year - 2022

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc21-2019

Subject(s) - medicine , randomized controlled trial , cost–benefit analysis , marginal cost , willingness to pay , health care , cost effectiveness , quality adjusted life year , cost–utility analysis , type 2 diabetes , type 1 diabetes , economic evaluation , cost effectiveness analysis , diabetes mellitus , intensive care medicine , surgery , risk analysis (engineering) , economics , ecology , endocrinology , biology , microeconomics , economic growth , pathology

Hybrid closed-loop (HCL) therapy is an efficacious management strategy for young people with type 1 diabetes. However, high costs prevent equitable access. We thus sought to evaluate the cost-effectiveness of HCL therapy compared with current care among young people with type 1 diabetes in Australia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research